Cano HR, Ruiz-Healy ÁF, Matti AN, Robredo TV, Flores AM

Language: Spanish
References: 6
Page: 71-77
PDF size: 108.36 Kb.

ABSTRACT

Purpose: To evaluate the effects of intravitreal bevacizumab on visual acuity and choroidal neovascularization in patients with age-related macular degeneration.
Materials and methods: Prospective study of patients with neovascular age- related macular degeneration, with no previous treatment. All with complete ophthalmologic examination including: visual acuity, intra ocular pressure, fluorescein angiography and optical coherence tomography, before and after, administration of intravitreal bevacizumab, with at least one month follow up.
Results: Fifteen eyes of 14 patients, ten females and four males, with an average age of 76 years. The initial visual acuity averaged 20/170 (20/40–CF range), within one week of treatment the average visual acuity was 20/141 (20/30–20/800), and at one month follow up it was 20/149 (20/30–20/800). Optical coherence tomography showed an initial average macular thickness of 297m (157-478 range); at one-month follow it had declined to 287m(163-451).
Conclusions: Bevacizumab is an effective treatment in patients with choroidal neovascularization due to age-related macular degeneration. It maintained visual acuity in 11 of 15 treated eyes (73.3%), and it improved visual acuity in 33.3% of eyes at one-month follow up. Only two eyes (13%) showed a decline in visual acuity at one month.

REFERENCES

1. Michels S, Rosenfeld P, Puliafito C y cols. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration. Twelve-week results of an uncontrolled openlabel clinical study. Ophthalmology 2005; 112:1035–1047.

2. Ng E, Adamis A. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 2005; 40:352–68.

3. Lip P, Blann A, Hope-Ross M, Gibson J, Lip G. Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology and endothelial dysfunction. Ophthalmology 2001; 108:705–710.

4. Rosenfeld P, Moshfeghi A, Puliafito C. Optical coherent tomography findings after intravitreal injection of bevacizumab for neovascular age-related macular degeneration. Ophthalmic Surgery, Lasers & Imaging 2005; 36(4):331-335.

5. Rosenfeld P, Schwartz S, Blumenkranz M, Miller J, Haller J, Reimann J, Greene W. Maximum tolerated dose of a humanized anti–vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005; 112:1048–1053.

6. The Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Phase II Study Results. Ophthalmology 2003; 110:979–986.